One of the most dangerous threats to healthcare in Africa is not always disease—it is the medicine itself. Counterfeit and substandard drugs continue to infiltrate supply chains across the continent, silently undermining treatment outcomes, eroding trust in healthcare systems, and costing lives.
For years, pharmacists and regulators have fought this battle with limited tools: manual inspection, fragmented reporting systems, and reactive enforcement. While these efforts have made progress, they are no longer sufficient for the scale and sophistication of today’s counterfeit drug networks. The problem has evolved—and so must the solution.
Artificial Intelligence (AI) now presents Africa with an opportunity to leapfrog traditional systems and redefine pharmaceutical safety. The question is no longer whether we can detect counterfeit medicines—but how quickly we can scale intelligent systems that make detection proactive, accessible, and reliable.
The hidden cost of counterfeit medicines
Counterfeit medicines do more than fail to treat disease. They contribute to drug resistance, prolong illness, increase healthcare costs, and, in many cases, lead to preventable deaths. For chronic and specialty patients, the risks are even more severe. A cancer patient receiving a falsified oncology drug or a diabetic patient using ineffective insulin is not just experiencing treatment failure—they are losing critical time.
Beyond clinical outcomes, counterfeit drugs damage trust. Patients begin to question the authenticity of medicines, even when they are genuine. This erosion of confidence affects adherence, health-seeking behaviour, and ultimately, the credibility of the entire pharmaceutical ecosystem.
Why traditional detection methods are failing
Most counterfeit detection systems in Africa are reactive. They depend heavily on regulatory crackdowns, sporadic quality checks, and reports after harm has already occurred. Pharmacists often rely on visual cues—packaging, labelling, and supplier reputation—which counterfeiters are increasingly able to replicate with alarming precision. We also have mobile authentication solutions that have been introduced by some pharma companies
Supply chains are also fragmented, involving multiple intermediaries, informal markets, and cross-border movement. This complexity makes it difficult to trace medicines from manufacturer to patient, creating gaps that counterfeit products exploit.
In essence, we are trying to solve a 21st-century problem with 20th-century tools.
AI as a game-changer in drug safety
AI changes the equation by enabling real-time, scalable, and intelligent detection of counterfeit medicines.
With advances in computer vision, machine learning, and data analytics, AI systems can:
- Analyse packaging patterns and detect subtle inconsistencies invisible to the human eye
- Verify batch numbers and supply chain data instantly
- Identify anomalies across large datasets of medicine distribution
- Learn and improve continuously as new counterfeit patterns emerge
Imagine a pharmacist scanning a drug pack with a smartphone and receiving immediate verification of authenticity. Imagine a system that flags suspicious batches before they reach patients. This is not futuristic—it is achievable today.
At HubPharm Africa, we are actively building toward this reality through Afiya—our AI-powered platform designed not only to support adherence but also to enhance medicine safety. By integrating counterfeit detection into everyday pharmacy workflows, we can move from reactive detection to proactive prevention.
Embedding AI into pharmacy practice
For AI to truly transform pharmaceutical safety, it must be embedded into the daily operations of pharmacists and healthcare providers.
This means:
- Integrating AI tools into dispensing workflows
- Training pharmacists to use digital verification systems
- Connecting pharmacies to centralised intelligence platforms
- Encouraging real-time reporting and feedback loops
Pharmacists are the last line of defence before medicines reach patients. Empowering them with AI tools strengthens this role and elevates pharmacy practice from product dispensing to active quality assurance.
The role of policy and collaboration
Technology alone cannot solve the counterfeit drug problem. It must be supported by strong policy frameworks and multi-stakeholder collaboration.
- Regulators such as NAFDAC and other national agencies must:
- Support the adoption of AI-powered verification systems
- Enable data sharing across supply chain stakeholders
- Strengthen digital traceability standards
- Encourage innovation through regulatory sandboxes
Pharmaceutical companies, distributors, and technology providers must also collaborate to build interoperable systems that ensure transparency across the supply chain.
Sesan Kareem is a licensed pharmacist, health systems strategist, and serial entrepreneur with over a decade of experience in pharmacy management, healthcare consulting, and organisational leadership. He previously served as regional sales manager at Pharmaplus and PA to the President of the Pharmaceutical Society of Nigeria, giving him deep insight into Nigeria’s pharmaceutical supply chain and regulatory landscape. Sesan is the Founder of HubPharm Africa and HubCare Health.
